Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation

Phase 2 Active not recruiting 43 enrolled Harbin Medical University

NaSingle-groupOpen-labelTreatment

Summary

To observe and evaluate the efficacy and safety of neoadjuvant long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib Mesylate in the treatment of locally advanced rectal cancer and low-lying rectal cancer with sphincter-preservation demand.

Timeline

Start: 2026-05-29
Primary completion: 2028-05-29
Completion: 2029-05-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adebrelimab	Monoclonal antibody	1200 mg	Intravenous
Subject	Rivoceranib	Small molecule	250 mg	Oral
Background	Capecitabine	Small molecule	1650 mg/m2	—

Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation

Summary

Timeline

Drugs

Indications